PreprintAll rights reservedbioRxiv
Choline Kinase Alpha Inhibition is a Mutation Agnostic Therapeutic Vulnerability in Clonal Hematopoiesis
- 1Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Boston, MA, Howard Hughes Medical Institute
Related
- A therapeutic vulnerability linking MNK1/2 inhibition and G1/S cyclin-dependent kinase blockade in triple-negative breast cancer
- Therapeutic NAMPT inhibition reveals a targetable metabolic vulnerability in neuroblastoma.
- More Than Half of DNMT3A-Mutant Patients in Pooled Public Cancer Genomic Data Carry No Tumor-Derived Mutation: Clonal Hematopoiesis Introduced by Patient-Keyed Aggregation
- Cell-state-dependent responses to PLK1 inhibition reveal a non-canonical microtubule-endolysosomal vulnerability in quiescent leukemia stem cells
- Vulnerability of triple negative breast cancer to daraxonrasib pan-RAS(on) inhibition
BibTeX
@misc{gheller2026choline,
title = {{Choline Kinase Alpha Inhibition is a Mutation Agnostic Therapeutic Vulnerability in Clonal Hematopoiesis}},
author = {B. J. Gheller and O. Mitchell and M. Quach and J. Gopakumar and S. Avagyan and S. Yang and T. P. Mathews and C. Haggerty and A. Meissner and J. Garcia and R. J. DeBerardinis and S. Jaiswal and F. Camargo and L. I. Zon},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.26.760729},
url = {https://www.biorxiv.org/content/10.64898/2026.10.26.760729v1},
}
RIS
TY - UNPB
TI - Choline Kinase Alpha Inhibition is a Mutation Agnostic Therapeutic Vulnerability in Clonal Hematopoiesis
AU - B. J. Gheller
AU - O. Mitchell
AU - M. Quach
AU - J. Gopakumar
AU - S. Avagyan
AU - S. Yang
AU - T. P. Mathews
AU - C. Haggerty
AU - A. Meissner
AU - J. Garcia
AU - R. J. DeBerardinis
AU - S. Jaiswal
AU - F. Camargo
AU - L. I. Zon
PY - 2026
DA - 2026/10/26
PB - bioRxiv
DO - 10.64898/2026.10.26.760729
UR - https://www.biorxiv.org/content/10.64898/2026.10.26.760729v1
SN - 2692-8205
ER -